Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Abstract

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).

Keywords

Affiliated Institutions

• University College Dublin IE
• Central Clinical Hospital and Polyclinic RU
• University of Tübingen DE
• Ivano-Frankivsk National Medical University UA
• University College London GB
• Georgetown Lombardi Comprehensive Cancer Center
• Université Laval CA
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Lyon College US
• Rocky Mountain Cancer Centers US
• Barts Health NHS Trust GB
• Wojskowy Instytut Medycyny Lotniczej PL
• Ministry of Health UA
• The Christie NHS Foundation Trust GB
• Dnipropetrovsk State Medical Academy UA
• Université Côte d'Azur FR
• Taipei Veterans General Hospital TW
• Tallaght University Hospital IE
• Cleveland Clinic US
• Hospital de Clínicas de Porto Alegre BR
• Sumy State University UA
• Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology RU
• P.A. Hertzen Moscow Oncology Research Institute RU
• Osaka City University Hospital JP
• Palacký University Olomouc CZ
• Centre Antoine Lacassagne FR
• Queen Mary University of London GB
• Centre Hospitalier de l’Université de Montréal CA
• Fox Chase Cancer Center US
• The Royal Free Hospital GB

Related Publications